Two γδ17 T cell subsets can be major sources of IL‐17 at tumor sites: Vγ4+ γδ17 T cells predominate in hepatocellular carcinoma [20] and in breast tumor murine models [21], whereas Vγ6+ γδ17 T cells are enriched in lung [22], ovarian [23], and cervical [24] tumor mouse models (Fig. 1). This evidence concerns the gene IL17A and neoplasm.